NCT02811861 2026-02-23
CLEAR
Eisai Inc.
Phase 3 Active not recruiting
Clinical Trials
36 trialsNCT03673501 2026-02-05
INTRIGUE
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07218926 2026-01-30
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
GlaxoSmithKline
Phase 3 Recruiting
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03091192 2026-01-23
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT06726421 2026-01-15
STROKER
Sun Yat-sen University
Phase 3 Recruiting
NCT05734105 2025-12-17
INSIGHT
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT04394975 2025-11-28
Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Completed
NCT07165418 2025-09-10
A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI
Peking University Cancer Hospital & Institute
Phase 3 Not yet recruiting
NCT00930033 2025-09-05
CARMENA
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT03260894 2025-07-29
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT02231749 2025-06-26
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT03141177 2025-06-06
CheckMate 9ER
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05043090 2025-05-08
SAMETA
AstraZeneca
Phase 3 Active not recruiting
NCT00720941 2025-03-30
COMPARZ
Novartis
Phase 3 Completed
NCT04523272 2024-10-15
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Active not recruiting
NCT04409223 2024-02-09
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated
NCT03729245 2023-04-11
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics
Phase 3 Terminated
NCT02420821 2023-01-30
IMmotion151
Hoffmann-La Roche
Phase 3 Completed
NCT01694277 2020-12-08
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
AB Science
Phase 3 Completed
NCT00375674 2018-09-21
S-TRAC
Pfizer
Phase 3 Completed
NCT01265901 2017-10-12
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
Immatics Biotechnologies GmbH
Phase 3 Completed
NCT01064310 2017-04-17
PISCES
Novartis
Phase 3 Completed
NCT00457691 2015-03-30
Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
Pfizer
Phase 3 Completed
NCT00457392 2013-10-29
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
Pfizer
Phase 3 Completed
NCT00699374 2013-01-14
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
Pfizer
Phase 3 Terminated
NCT00393939 2012-07-19
SUN 1064
Pfizer
Phase 3 Completed
NCT00435409 2012-06-26
A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer
Pfizer
Phase 3 Completed
NCT00471328 2012-06-12
ENEST
Novartis
Phase 3 Completed
NCT00372567 2011-03-17
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Pfizer
Phase 3 Terminated
NCT00428597 2010-10-11
A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
Pfizer
Phase 3 Terminated
NCT00083889 2010-01-26
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Pfizer
Phase 3 Completed
NCT00075218 2009-09-28
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
Pfizer
Phase 3 Completed